Skip to main content
CLRB logo

CLRB · Cellectar Biosciences, Inc. · Earnings Call Transcripts & Audio

Track CLRB — free
$2.34 -0.07 (-2.90%) At close · Sep 9
Market Cap
$22.78M
Shares
9.45M

Cellectar Biosciences, Inc. Earnings Call Transcripts

Quarterly earnings calls for Cellectar Biosciences, Inc. (CLRB), with available speaker-labelled transcripts, captured audio replays, call highlights, 8-K earnings releases and periodic filings. Investor days and conferences appear here too.

Earnings call
FY26 · Q2
2026-08-13
Cellectar Biosciences, Inc. (CLRB) Q2 2026 Earnings Call Transcript
Confident tone PDC platform and pipeline expansion Financing and balance sheet Regulatory path and accelerated approval
Diluted EPS
$-0.57
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-05-14
Cellectar Biosciences, Inc. (CLRB) Q1 2026 Earnings Call Transcript
Confident tone Waldenstrom Macroglobulinemia unmet need Phase III confirmatory trial design Iopofosine I-131 CLOVER WaM Phase IIb data
Diluted EPS
$-1.33
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-03-04
Cellectar Biosciences, Inc. (CLRB) Q4 2025 Earnings Call Transcript
Confident tone Regulatory progress in EU and US Iapophysine I-131 / WM lead asset Data readouts and upcoming medical presentations
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-13
Cellectar Biosciences, Inc. (CLRB) Q3 2025 Earnings Call Transcript
Confident tone Regulatory progress for iopofosine I-131 Next-generation pipeline (CLR125, CLR225) PFS data and disclosure timing
Diluted EPS
$-1.41
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-14
Cellectar Biosciences, Inc. (CLRB) Q2 2025 Earnings Call Transcript
Confident tone Regulatory pathway for Iopofosine I-131 in WM Next-generation pipeline European regulatory strategy
Diluted EPS
$-3.39
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-13
Cellectar Biosciences, Inc. (CLRB) Q1 2025 Earnings Call Transcript
Positive tone FDA and EMA regulatory pathway Phase 3 study design and comparator Iopofosine I 131 for Waldenstrom's Macroglobulinemia
Diluted EPS
$-4.30
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-13
Cellectar Biosciences, Inc. (CLRB) Q4 2024 Earnings Call Transcript
Balanced tone iopofosine / iapopacine clinical data and CLOVER-WaM Regulatory pathway and NDA delay Phase 3 study design and timeline
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-18
Cellectar Biosciences, Inc. (CLRB) Q3 2024 Earnings Call Transcript
Confident tone Confirmatory study requirements NDA submission and regulatory timeline CLOVER WaM pivotal study data
Diluted EPS
$-12.13
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-07-23
Cellectar Biosciences, Inc. (CLRB) Q2 2024 Earnings Call Transcript
Positive tone CLOVER WaM pivotal study data NDA filing and FDA review Manufacturing and CMC
Diluted EPS
$-5.43
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-14
Cellectar Biosciences, Inc. (CLRB) Q1 2024 Earnings Call Transcript
Confident tone WM pivotal study and NDA submission Commercial launch preparation and pricing Manufacturing and supply chain readiness
Diluted EPS
$-27.30
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-03-27
Cellectar Biosciences, Inc. (CLRB) Q4 2023 Earnings Call Transcript
Confident tone CLOVER-WaM pivotal trial results NDA filing and regulatory pathway European expansion strategy
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-02
Cellectar Biosciences, Inc. (CLRB) Q3 2023 Earnings Call Transcript
Diluted EPS
$-46.50
Audio Transcript Slides 8-K10-Q
Showing 1–12 of 12 earnings calls
Key facts CIK 1279704 CUSIP 15117F880 13F (30d) 23 filings 23 filers Visit website Investor relations